No Data
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Sangamo Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5
Earnings Update: Here's Why Analysts Just Lifted Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target To US$3.80
Q2 2024 Sangamo Therapeutics Inc Earnings Call
WillLaw : still holding, time will tell, have a feeling
WillLaw : December 3.2
The real Honey bee OP WillLaw : Hope so friend
louis sss WillLaw : Long time no see (⊙o⊙) I really hope to see the auspicious number 3.2 next week